▎药明康德

新加坡，2022年4月28日 -- 药明康德旗下专注于细胞和基因疗法的CTDMO药明生基与新加坡科技研究局（新*科研）宣布开展全新合作，双方会将药明生基先进的TESSA™专利技术引入亚太地区。此次合作旨在促进细胞和基因疗法领域的科研创新，建立联合人才发展计划，为行业培养下一代GMP生产领域的科学家和工程师。

TESSA™技术是一种先进生产工艺，用于无须转染的规模化生产腺相关病毒（AAV），有助于大幅提高AAV的产量和质量，是AAV生产工艺发展的重要革新。据多项研究显示，基于TESSA™载体生产的AAV产量显著高于基于质粒生产的AVV，能够满足快速增长的医疗需求，为癌症和其他重症疾病患者带来福音。

随着合作项目的开展，药明生基将为TESSA™技术在新加坡的开发和商业化提供所需的材料、设备、资金和培训；新加坡科技研究局（新*科研）下属的生物处理科技研究院（BTI）将利用自身的合作伙伴体系助力药明生基在新加坡推动细胞和基因疗法的研发。

“我们很高兴与新加坡著名的BTI达成合作。”药明生基首席执行官张幼翔博士表示：“合作开发并商业化推广TESSA™技术是双方开启长期合作的第一步。”

新加坡科技研究局生物处理科技研究院院长许文忠博士表示：“BTI 在生物处理科学和工程方面拥有丰富的经验，我们很高兴能与药明生基在细胞和基因疗法领域开展合作，这意味着新加坡向创新疗法生物处理研发中心的目标迈近了重要的一步。”

关于药明生基

药明生基是药明康德旗下专注于细胞和基因疗法的CTDMO，致力于加速和变革基因和细胞治疗及其他高端治疗的开发、测试、生产和商业化。药明生基能够助力全球客户将更多创新疗法早日推向市场，造福病患。更多信息，请访问www.wuxiatu.com。

关于药明康德

药明康德（股票代码：603259.SH/2359.HK）为全球生物医药行业提供一体化、端到端的新药研发和生产服务，在亚洲、欧洲、北美等地均设有运营基地。药明康德通过独特的“CRDMO”和“CTDMO”业务模式，不断降低研发门槛，助力客户提升研发效率，为患者带来更多突破性的治疗方案，服务范围涵盖化学药研发和生产、生物学研究、临床前测试和临床试验研发、细胞及基因疗法研发、测试和生产等领域。2021年，药明康德被MSCI评为ESG（环境、社会及管治）AA级。目前，公司的赋能平台正承载着来自全球30多个国家的5800多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com。

关于生物处理科技研究院

生物处理科技研究院（BTI）是新加坡科技研究局（新*科研）下属的研究机构。BTI成立于 1990 年，是新加坡生物生产领域的研发支柱。BTI的核心能力跨越整个生物工艺产业链，主要包括产品创新、细胞系开发、培养基开发、下游加工、工艺开发和放大以及分析科学与技术。通过战略合作伙伴关系和应用研究，BTI致力于在多个产品市场创造价值和影响力，包括生物制剂、细胞和基因治疗、外泌体、疫苗、工程化组织、过程分析技术和细胞培养系统。有关BTI的更多信息，请浏览 www.a-star.edu.sg/bti。

关于新加坡科技研究局

新加坡科技研究局（简称新*科研）是负责推动科学研发和打造创新技术的主导政府机构，致力于以经济为导向的研究。新*科研通过与公共和私人机构的开放式创新合作，助力提升社会民众的生活质量。

身为一所科学与科技组织，新*科研成功地将学术界知识转化成为行业实施。新*科研的研究大力促进新加坡经济增长，打造就业机会，通过提高医疗保健、城市生活和可持续性发展领域方面的社会效益来改善人民生活。

新*科研积极帮助业界人员和本机构及旗下多所研究院的人才培养。新*科研的研究院主要坐落于启奥城和启汇城，研究项目跨越生物医药研究和科学工程研究各大领域。更多信息，请访问 www.a-star.edu.sg。

---

WuXi Advanced Therapies and A*STAR announce partnership to advance cell and gene therapy in the Asia-Pacific region

28 April 2022 – SINGAPORE. WuXi Advanced Therapies (WuXi ATU), a wholly owned subsidiary of WuXi AppTec, and A*STAR’s Bioprocessing Technology Institute (BTI), announced a new partnership to bring WuXi ATU’s proprietary Tetracycline-Enabled Self-Silencing Adenovirus (TESSA™) technology to the Asia-Pacific region. This partnership aims to foster scientific innovation in cell and gene therapy, and establish a joint professional development programme to train and develop the next generation of scientists and engineers in GMP manufacturing for the cell and gene therapy industry. 

TESSA™ technology is a novel process for transfection-free, scalable manufacture of adeno-associated viruses (AAV) and represents a major advancement in AAV manufacturing by improving AAV yields and particle quality. TESSA™ technology produces significantly more AAV than plasmid-based manufacturing, generating enough material to address the growing demand in healthcare needs for patients suffering from cancer and other life-threatening diseases. 

As part of this collaboration, WuXi ATU will supply the materials, equipment, funding, and training required to further develop and commercialise TESSA™ technology in Singapore. BTI will contribute research expertise, facilities and access to its network of partners to support WuXi ATU in its research and development in cell and gene therapy in Singapore.

“We are delighted to launch this collaboration with Singapore’s renowned Bioprocessing Technology Institute,” said David Chang, CEO of WuXi Advanced Therapies. “We hope that working together on the development and commercialisation of TESSA™ technology will be the first step in a long-term partnership.”

Dr Koh Boon Tong, Executive Director of A*STAR’s Bioprocessing Technology Institute added, “With BTI’s extensive experience in bioprocessing science and engineering, we are excited to collaborate with WuXi ATU in the area of advanced cell and gene therapy and further R&D together. This is a significant step towards Singapore’s goal to be an innovative biotherapeutics bioprocessing R&D hub.” 

About WuXi Advanced Therapies (WuXi ATU)

As the advanced therapies business unit of WuXi AppTec, WuXi Advanced Therapies is a Contract Testing, Development and Manufacturing Organization (CTDMO) that offers integrated platforms to transform the discovery, development, testing, manufacturing, and commercialization of cell and gene therapies. Our services and solutions accelerate time to market and support customer programs around the world. For more information, please visit https://www.advancedtherapies.com

About WuXi AppTec

As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable global pharmaceutical and healthcare industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, cell and gene therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received AA ESG rating from MSCI in 2021 and its open-access platform is enabling more than 5,800 collaborators from over 30 countries to improve the health of those in need – and to realize the vision that “every drug can be made and every disease can be treated.” Please visit: http://www.wuxiapptec.com

About A*STAR’s Bioprocessing Technology Institute

Bioprocessing Technology Institute (BTI) is a research institute under A*STAR. Established in 1990, BTI is positioned as Singapore’s pillar of research and development for the biomanufacturing sector. BTI’s core capabilities span across the bioprocessing value chain, largely comprising Product Innovation, Cell Line Development, Media Development, Downstream Processing, Process Development and Scale-up, and Analytical Science & Technologies. Through strategic partnerships and application-driven research, BTI seeks to create value and impact in product markets including biologics, cell and gene therapy, exosomes, vaccines, engineered tissues, process analytical technologies and cell culture systems. For more information on BTI, visit www.a-star.edu.sg/bti.

About the Agency for Science, Technology and Research (A*STAR)

The Agency for Science, Technology and Research (A*STAR) is Singapore's lead public sector R&D agency. Through open innovation, we collaborate with our partners in both the public and private sectors to benefit the economy and society. As a Science and Technology Organisation, A*STAR bridges the gap between academia and industry. Our research creates economic growth and jobs for Singapore, and enhances lives by improving societal outcomes in healthcare, urban living, and sustainability. A*STAR plays a key role in nurturing scientific talent and leaders for the wider research community and industry. A*STAR’s R&D activities span biomedical sciences to physical sciences and engineering, with research entities primarily located in Biopolis and Fusionopolis. For ongoing news, visit www.a-star.edu.sg.

分享，点赞，在看，聚焦全球生物医药健康创新